LPHN3 and Attention-Deficit/Hyperactivity Disorder: a susceptibility and pharmacogenetics study.

LPHN3 and Attention-Deficit/Hyperactivity Disorder: a susceptibility and pharmacogenetics study.

Genes Brain Behav. 2015 May 19;

Authors: Bruxel EM, Salatino-Oliveira A, Akutagava-Martins GC, Tovo-Rodrigues L, Genro JP, Zeni CP, Polanczyk GV, Chazan R, Schmitz M, Arcos-Burgos M, Rohde LA, Hutz MH

Abstract
Latrophilin 3 (LPHN3) is a brain-specific member of the G-protein coupled receptor family associated to both Attention-Deficit/Hyperactivity Disorder (ADHD) genetic susceptibility and methylphenidate pharmacogenetics.. Interactions of LPHN3 variants with variants harbored in the 11q chromosome improve the prediction of ADHD development and medication response. The aim of the present study was to evaluate the role LPHN3 variants in childhood ADHD susceptibility and treatment response in a naturalistic clinical cohort. The association between LPHN3 and ADHD was evaluated in 523 children and adolescents with ADHD and 132 controls. In the pharmacogenetics study, 172 children with ADHD were investigated. The primary outcome measure was the parent-rated Swanson, Nolan, and Pelham Scale – version IV applied at baseline, first and third months of treatment with methylphenidate. The results reported herein suggest the CGC haplotype derived from SNPs rs6813183, rs1355368, rs734644 as an ADHD risk haplotype (P = 0.02; OR = 1.46). Although non-significant after multiple testing correction, its interaction with the 11q chromosome SNP rs965560 slightly increases risk (nominal P = 0.03; OR = 1.55). Homozygous individuals for the CGC haplotype showed faster response to MPH treatment as a significant interaction effect between CGC haplotype and treatment over time was observed (P < 0.001). Homozygous individuals for the GT haplotype derived from SNPs rs6551665 and rs1947275 showed a significant interaction with treatment over time (nominal P = 0.04). Our findings replicate previous findings reporting that LPHN3 confers ADHD susceptibility, and moderates MPH treatment response in children and adolescents with ADHD.

PMID: 25989180 [PubMed – as supplied by publisher]

via http://ift.tt/1FzY9cJ